China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC), SYS6010, which is intended for the treatment of advanced solid tumors.
Pre-Clinical Studies and Patent Protection for SYS6010
Pre-clinical studies have demonstrated that SYS6010, for which patent protection has been sought both domestically and internationally, exhibits good anti-tumor activities across a range of cancers. This approval marks a significant step forward in the development of SYS6010 as a potential treatment option for patients with advanced solid tumors.-Fineline Info & Tech
